KALETRA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug KALETRA contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII 2494G1JF75 - LOPINAVIR
 

Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. Inhibition of HIV protease prevents cleavage of the gag-pol polyprotein resulting in the production of immature, non-infectious virus.

 
Read more about Lopinavir
2
UNII O3J8G9O825 - RITONAVIR
 

Ritonavir is an orally active peptidomimetic inhibitor of the HIV-1 and HIV-2 aspartyl proteases. Inhibition of HIV protease renders the enzyme incapable of processing the gag-pol polyprotein precursor which leads to the production of HIV particles with immature morphology that are unable to initiate new rounds of infection. Ritonavir has selective affinity for the HIV protease and has little inhibitory activity against human aspartyl proteases. Pharmacokinetic enhancement by ritonavir is based on ritonavir’s activity as a potent inhibitor of CYP3A-mediated metabolism.

 
Read more about Ritonavir

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 KALETRA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 KALETRA Oral solution MPI, EU: SmPC European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
J05AR10 J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
AU Pharmaceutical Benefits Scheme 10272P, 10285H, 10327M
BR Câmara de Regulação do Mercado de Medicamentos 543715110002017, 543715110002117, 543715110002217, 543715110002317
CA Health Products and Food Branch 02243644, 02285533, 02312301
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 562-MEE-1214
EE Ravimiamet 1082472, 1284320, 1367030, 1462766, 1750902
ES Centro de información online de medicamentos de la AEMPS 01172003, 01172006, 01172008
FI Lääkealan turvallisuus- ja kehittämiskeskus 003974, 053043, 114019
FR Base de données publique des médicaments 64629002, 67969992, 69474926
GB Medicines & Healthcare Products Regulatory Agency 106255, 136315, 350552, 382345, 46902
HK Department of Health Drug Office 48165, 55200, 58310
IL מִשְׂרַד הַבְּרִיאוּת 4789, 6647, 6648
JP 医薬品医療機器総合機構 6250101F1037, 6250101S1035
LT Valstybinė vaistų kontrolės tarnyba 1010318, 1028883, 1028884, 1031776, 1064026, 1064027, 1084285
MX Comisión Federal para la Protección contra Riesgos Sanitarios 219M2006, 556M2000
NL Z-Index G-Standaard, PRK 59439, 81094, 86142
NZ Medicines and Medical Devices Safety Authority 12243, 13159, 9848
PL Rejestru Produktów Leczniczych 100108438, 100162395, 100192663
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W64677001, W64677002, W64678001
SG Health Sciences Authority 11492P, 13250P, 13713P
TN Direction de la Pharmacie et du Médicament 4683021H
TR İlaç ve Tıbbi Cihaz Kurumu 8680656080094, 8680656080100
US FDA, National Drug Code 0074-0522, 0074-1575, 0074-2605, 0074-3956, 0074-6799, 55289-947, 70518-0091
ZA Health Products Regulatory Authority 35/20.2.8/0255

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.